T he past 4 decades have witnessed amazing and once unimaginable advances in the management of cardiovascular diseases. However, the trajectory of progress has rarely been linear and the path often strewn with obstacles. Experience has taught us that innovations often beget unforeseen problems. This lesson was quickly learned from the introduction of surgically implantable prosthetic valves, in which optimism that valve replacement had "solved" the scourge of stenosis and regurgitation was tempered by realization that these devices had created the unexpected chronic condition of "prosthetic valve disease," characterized by the maladies of valve thrombosis, complications of anticoagulant agents, prosthetic endocarditis, and patient-valve mismatch (1) .
The saga of percutaneous management of coronary artery disease (CAD) is similarly punctuated by thrilling advances subdued by unanticipated consequences. Bare metal stents (BMS) were introduced with the expectation that they would obviate the challenges of acute closure and restenosis that limited balloon angioplasty. The hope that BMS might be a "free lunch" was dashed when the "bill came due" with recognition of their attendant complications of acute stent thrombosis (ST) and later in-stent restenosis (ISR). These limitations gave birth to drugeluting stents, which although a major advance, unfortunately proved to be less than a "pure cure," reducing but not eliminating ST and ISR, and compelling the burdens of prolonged dual antiplatelet therapy (DAPT).
Thus, metallic coronary stents constitute both a remedy and a "disease." However, as emphasized in the paper by Garcia-Garcia et al. (2) in this issue of iJACC, the advent of bioresorbable coronary stress may represent a paradigm shift that cuts the "Gordian knot" that inextricably linked stents to metallicinduced complications and encumbrances. This This piece comprehensively reviews the distinct designs and benefits of the BRS, focusing on the compelling clinical advantages these devices may offer. As eloquently emphasized, BRS represent a "revolutionary change in applying local coronary therapies" and offer the "unique ability to provide a temporary scaffold that is necessary to maintain the patency of the vessel after intervention, releasing antiproliferative drugs and then they gradually degrade, liberating the vessel from its cage, permitting the restoration of vascular physiology and integrity." The paper reviews data to support the novel and provocative concept that implantation of BRS rather than permanent metallic cages may facilitate restoration of "vessel vasomotor tone, adaptive shear stress, late luminal enlargement, and late expansive remodeling." Of great practical impact, they emphasize that "advantages over metallic stents include reduced thrombotic propensity, which will hopefully mitigate the burdens of DAPT" (2) .
An enlightening component of the present paper is the contrapuntal weaving of the importance of advances in direct coronary imaging to development of coronary therapeutics. The paper will be valued as a scholarly primer on "methods and parameters" relevant to assessing CAD and stents in general, and 
